DAB
Publication/Presentation Date
12-1-2017
Abstract
CONTEXT: We have reported previously that DAB389IL-2 recombinant fusion toxin targets IL-2R bearing CD4
OBJECTIVES: The present study was undertaken to investigate the effect of DAB389IL-2 treatment on various cytokine-secreting cell populations in A-EAE and C-EAE mice.
MATERIALS AND METHODS: The effects of DAB389IL-2 at doses of 200-, 800-, or 1600 kU administered i.v. on days 11-13 and 15 on the clinical score and cytokine-secreting cell populations were examined using flow cytometry.
RESULTS: C-EAE mice treated with 1600kU DAB389IL-2, but not A-EAE mice treated with 800 kU had significantly reduced disease. The CD3+CD25+ sub-population in spleens and spinal cords of A-EAE mice treated with 800 kU DAB389IL-2 a was increased, whereas in C-EAE mice treated with 1600 kU this population was increased. DAB
DISCUSSION AND CONCLUSIONS: Our study demonstrates that DAB
Volume
39
Issue
6
First Page
318
Last Page
329
ISSN
1532-2513
Published In/Presented At
Bhopale, M. K., Hilliard, B., Constantinescu, C. S., Phillips, S. M., & Rostami, A. (2017). DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice. Immunopharmacology and immunotoxicology, 39(6), 318–329. https://doi.org/10.1080/08923973.2017.1369099
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
28929835
Department(s)
Administration and Leadership
Document Type
Article